Physician profile
Caroline Leibowitz
NPI 1114532173
$10,098.38
in general payments reported to CMS, 2019-2025
40 companies · $3,790 in 2025
The $3,790 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $1,570 · 2023: $2,086 · 2024: $1,984 · 2025: $3,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,754 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,754.17 |
| Education | $106.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,753.93 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,120.58 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $980.84 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $944.90 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $725.41 | 2021-2025 | |
| Amgen INC. | $480.93 | 2021-2025 | Uplizna |
| Celgene Corporation | $377.93 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $377.66 | 2021-2025 | Omvoh |
| Madrigal Pharmaceuticals | $334.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $291.71 | 2022-2025 | |
| Qol Medical, LLC | $282.79 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $269.18 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $216.81 | 2022-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $205.85 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $184.87 | 2022-2025 | Nucala, Shingrix |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.24 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2022 | |
| Ferring Pharmaceuticals INC. | $119.50 | 2022-2024 | Rebyota, Clenpiq, Cimzia |
| Ipsen Biopharmaceuticals, INC | $112.76 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $110.62 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.22 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $99.39 | 2024-2025 | Vegzelma |
| Sanofi-Aventis U.S. LLC | $85.33 | 2021 | |
| Phathom Pharmaceuticals, INC. | $69.19 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $63.78 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $44.58 | 2023 | Ocaliva |
| Intra-Sana Laboratories | $44.39 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Amarin Pharma, INC. | $40.97 | 2021 | |
| Merck Sharp & Dohme LLC | $38.18 | 2022-2023 | Dificid |
| Braintree Laboratories, INC. | $33.45 | 2023-2025 | Suflave, Sutab |
| Eisai INC. | $29.93 | 2021 | |
| Organon LLC | $29.16 | 2023 | Renflexis, Hadlima |
| Sandoz INC. | $25.35 | 2025 | Hyrimoz |
| Evoke Pharma, INC. | $17.94 | 2025 | |
| Fresenius Kabi USA, LLC | $16.39 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $15.46 | 2023 | Terlivaz |
| Janssen Pharmaceuticals, INC | $13.81 | 2021 | |
| Genentech USA, INC. | $13.54 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.